{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:56:39Z","timestamp":1787849799491,"version":"build-2784847793"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23ck0106670h0003"],"award-info":[{"award-number":["23ck0106670h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00428-024-03764-1","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T05:02:06Z","timestamp":1707800526000},"page":"465-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy"],"prefix":"10.1007","volume":"484","author":[{"given":"Yuto","family":"Kaimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhi","family":"Makino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Makita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitose","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7251-7920","authenticated-orcid":false,"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"3764_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.85","author":"CA van der Weyden","year":"2017","unstructured":"van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM (2017) Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. https:\/\/doi.org\/10.1038\/bcj.2017.85","journal-title":"Blood Cancer J"},{"key":"3764_CR2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"NM Okeley","year":"2010","unstructured":"Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16:888\u2013897. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2069","journal-title":"Clin Cancer Res"},{"key":"3764_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/cup.13545","volume":"46","author":"A Goyal","year":"2019","unstructured":"Goyal A, Patel S, Goyal K, Morgan EA, Foreman RK (2019) Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J Cutan Pathol 46:823\u2013829. https:\/\/doi.org\/10.1111\/cup.13545","journal-title":"J Cutan Pathol"},{"key":"3764_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/cup.12797","volume":"43","author":"RN Al-Rohil","year":"2016","unstructured":"Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP (2016) Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol 43:1161\u20131166. https:\/\/doi.org\/10.1111\/cup.12797","journal-title":"J Cutan Pathol"},{"key":"3764_CR5","doi-asserted-by":"publisher","unstructured":"Arai H, Furuichi S, Nakamura Y, Nakamura Y, Ichikawa M, Mitani K (2016) ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. Rinsho Ketsueki 57:634\u2013637. Japanese. https:\/\/doi.org\/10.11406\/rinketsu.57.634","DOI":"10.11406\/rinketsu.57.634"},{"key":"3764_CR6","unstructured":"WHO Classification of Tumours Editorial Board (2022) Hematolymphoid tumors [Internet; beta version ahead of print (in progress)]. Lyon (France): International Agency for Research on Cancer. (WHO classification of tumors series, 5th ed.). https:\/\/tumourclassification.iarc.who.int. Accessed 18 June 2023"},{"key":"3764_CR7","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1097\/PAS.0000000000001941","volume":"46","author":"AL Feldman","year":"2022","unstructured":"Feldman AL, Oishi N, Ketterling RP, Ansell SM, Shi M, Dasari S (2022) Immunohistochemical approach to genetic subtyping of anaplastic large cell lymphoma. Am J Surg Pathol 46:1490\u20131499. https:\/\/doi.org\/10.1097\/PAS.0000000000001941","journal-title":"Am J Surg Pathol"},{"key":"3764_CR8","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parrilla Castellar","year":"2014","unstructured":"Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL (2014) ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 124:1473\u20131480. https:\/\/doi.org\/10.1182\/blood-2014-04-571091","journal-title":"Blood"},{"key":"3764_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Tr\u00fcmper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Ill\u00e9s \u00c1, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, H\u00fcttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T (2022) The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 33:288\u2013298. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002","journal-title":"Ann Oncol"},{"key":"3764_CR10","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s00277-019-03853-1","volume":"99","author":"AM Maeshima","year":"2020","unstructured":"Maeshima AM, Taniguchi H, Fujino T, Saito Y, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K (2020) Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. Ann Hematol 99:2141\u20132148. https:\/\/doi.org\/10.1007\/s00277-019-03853-1","journal-title":"Ann Hematol"},{"key":"3764_CR11","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/j.1349-7006.2012.02307.x","volume":"103","author":"H Miyoshi","year":"2012","unstructured":"Miyoshi H, Arakawa F, Sato K, Kimura Y, Kiyasu J, Takeuchi M, Yoshida M, Ichikawa A, Ishibashi Y, Nakamura Y, Nakashima S, Niino D, Sugita Y, Ohshima K (2012) Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment. Cancer Sci 103:1567\u20131573. https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02307.x","journal-title":"Cancer Sci"},{"key":"3764_CR12","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","volume":"113","author":"J Hiraga","year":"2009","unstructured":"Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T (2009) Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 113:4885\u20134893. https:\/\/doi.org\/10.1182\/blood-2008-08-175208","journal-title":"Blood"},{"key":"3764_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbrc.2009.09.059","volume":"390","author":"T Sugimoto","year":"2009","unstructured":"Sugimoto T, TomitaA HJ, Shimada K, Kiyoi H, Kinoshita T, Naoe T (2009) Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 390:48\u201353. https:\/\/doi.org\/10.1016\/j.bbrc.2009.09.059","journal-title":"Biochem Biophys Res Commun"},{"key":"3764_CR14","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, Thomas SH, Forman SJ, Kane SE (2015) CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther 14:1376\u20131384. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0036","journal-title":"Mol Cancer Ther"},{"key":"3764_CR15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/PAS.0b013e3182759008","volume":"37","author":"AM Maeshima","year":"2013","unstructured":"Maeshima AM, Taniguchi H, Fukuhara S, Norikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobina K, Tsuda H (2013) Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy. Am J Surg Pathol 37:563\u2013570. https:\/\/doi.org\/10.1097\/PAS.0b013e3182759008","journal-title":"Am J Surg Pathol"},{"key":"3764_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12185-016-2018-y","volume":"104","author":"S Makita","year":"2016","unstructured":"Makita S, Maeshima AM, Taniguchi H, Kitahara H, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Kobayashi Y, Tobinai K (2016) Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma. Int J Hematol 104:396\u2013399. https:\/\/doi.org\/10.1007\/s12185-016-2018-y","journal-title":"Int J Hematol"},{"key":"3764_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/his.14910","volume":"83","author":"ML Marques-Piubelli","year":"2023","unstructured":"Marques-Piubelli ML, Kim DH, Medeiros LJ, Lu W, Khan K, Gomez-Bolanos LI, Rodriguez S, Parra ER, Ok CY, Aradhya A, Solis LM, Nieto YL, Steiner R, Ahmed S, Vega F (2023) CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology 83:143\u2013148. https:\/\/doi.org\/10.1111\/his.14910","journal-title":"Histopathology"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03764-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-03764-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03764-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T11:22:34Z","timestamp":1713266554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-03764-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["3764"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-03764-1","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"13 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of the National Cancer Center (2017\u2013342) and was conducted following the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}